Phase 2 trial of P-BCMA-101 for patients with relapsed/ refractory multiple myeloma
Latest Information Update: 20 May 2019
At a glance
- Drugs P-BCMA-101 (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Poseida Therapeutics
Most Recent Events
- 20 May 2019 New trial record
- 22 Apr 2019 According to a Be The Match BioTherapies media release, the company is enrolling patients in this trial and dosing is expected in the first half of 2019.